Marian Stevens
Kaly Stevens Kris Sarcoma Research Fund
•SEE HOW THE FUNDS ARE BEING USED. ANNUAL UPDATE LETTERS HAVE BEEN ADDED BELOW.
•Attention all weekend athletes: Become a member of Kaly's Crew, the event fundraising team for the Kaly Stevens Kris Sarcoma Research Fund. Started by Rob, his sister Mary, and cousin Brian, Kaly's Crew took to the streets of the five boroughs for it's initial event at the New York City Marathon in November 2015, designating the Kaly Stevens Kris Sarcoma Research fund as the direct recipient of all money raised through the team's website. In April 2016, Jason Starr, Kaly and Rob's friend and fellow alum of Consulate General Dubai, ran the Boston Marathon as a member of Kaly's Crew. And, Kaly's Crew has already begun recruiting members for this year's New York City Marathon, as Gaby Baca and Matt Appenfeller, friends of Kaly and Rob's, are currently training to complete the 26.2 mile race and raise money for Kaly's Research Fund.
If you are a runner, walker, cyclist, spinner, or whatever, sign up for an event, or, create an event where you live, and designate your team as Kaly's Crew. Specify the Kaly Stevens Kris Sarcoma Research Fund as the recipient of all money raised from your efforts. Contact Marian (KSKSRFund@gmail.com) for assistance in setting up a team website and donor page to assure that all money raised goes directly to Kaly's Research Fund.
Adored wife, beloved daughter, cherished and trusted friend, Kathryn Emily Stevens Kris passed away May 24, 2015 in Washington, DC from metastatic angiosarcoma. Artistic, musical, and athletic, with a radiant smile and wonderful laugh, she will be missed by all. In memory of Kaly, and to provide hope for others, we are establishing the Kaly Stevens Kris Sarcoma Research Fund at Memorial Sloan Kettering Cancer Center in New York, NY.
So There Is Hope
The Kaly Stevens Kris Sarcoma Research Fund is dedicated to supporting much-needed and on-going research efforts studying sarcoma at Memorial Sloan Kettering. Sarcomas are a group of rare cancers that affect the connective tissues of the body, such as fat, muscles, nerves, tendons, blood and lymph vessels, and bone. Angiosarcoma is a particularly rare and aggressive subtype.
Sarcomas can occur in any location in the body and affect individuals of all ages. Sarcomas often do not cause symptoms in the early stages, and there is not yet a routine screening test available to detect these tumors.
There are more than 70 different subtypes of sarcomas and sarcoma-like growths, and each year, there may be fewer than 1,000 cases of each type of sarcoma diagnosed in the United States. As such, it makes it even more difficult to develop treatments for each type of sarcoma. Oncologists, pathologists, nurses, surgeons, radiologists and others at institutions like Memorial Sloan Kettering and Johns Hopkins/Sibley Memorial Hospital are working to identify treatments tailored to each type and sub-type of sarcoma. While the number of clinical trials and availability of resources for sarcoma research have increased in the past few years, there is still a long way to go.
Through the Kaly Stevens Kris Sarcoma Research Fund, our goal is to support continued research for sarcoma -- particularly, angiosarcoma -- to not only develop new and innovative treatments, but more importantly, to provide hope to other patients and families facing these diseases and ultimately find a cure.
Thank you for your help and support!
David, Marian and Rob
July, 2022
Dear Friends and Family,
Seven years! You’ve continued to give throughout those years so that the research and programs benefiting sarcoma patients can be supported. Your generosity has brought the total of money raised to $230,000! We are always so grateful for your support in memory of Kaly, as are the team of doctors, researchers, patients and their family’s.
So many developments have recently been announced regarding new, promising treatments for many types of cancer, such as lung, breast and colon, relatively well funded areas of research. Sarcoma, a “rare” cancer, and so often underfunded, receives less support from the major sources. Our efforts and similar funding campaigns are vital for the research to continue. Below, Dr. Tap and his team have provided an update of their progress that you helped fund.
With fingers crossed, we are planning a Kaly’sCrew Sedona 2023 event at the RunSedona 5k/10K/Half Marathon in Sedona Arizona on Saturday, February 4th, 2023. Save the date, become a Team Member to help raise funds, participate in the event, or be a supporter from afar. This is a family friendly event so we welcome kids to participate in the race/walk and to be a part of all our group activities. As was done at the event in 2020, a wine and cheese gathering will be held the night before for those who have donated to the Kaly’sCrew fundraising, followed by a “no host” group dinner, probably at Sedona Pizza, a big hit in 2020. Participants will gather bright and early for the run/walk, then end the Sedona weekend with a “no host” group lunch, probably at Wildflower Cafe. These are the preliminary plans. As the event gets closer, detailed information will be provided regarding race registration, Kaly’sCrew Team Member sign-up, fundraising, and hotel suggestions. And all are encouraged to plan to continue the weekend in Flagstaff.
We are so grateful for your continued support, With our thanks,
David and Marian
Angiosarcoma Research at Memorial Sloan Kettering Cancer Center (MSK) July 2022
Prepared for: Marian Stevens
Sarcoma Disease Management Team: William Tap, MD, Chief of the Sarcoma Medical Oncology Service; Katherine Thornton, MD; Evan Rosenbaum, MD; Ciara Kelly, MBBCh BAO; Sujana Movva, MD; and Sandra D’Angelo, MD
The Cristina Antonescu Laboratory
Angiosarcoma — the type of sarcoma that Kaly Stevens had — is a rare and aggressive disease that accounts for 1 percent of all sarcoma diagnoses. Most patients start treatment with surgery and radiation therapy, but recurrence rates are as high as 45 to 100 percent. Metastasis (when cancer spreads from its original location) is common, and the five-year survival rate is only 30 percent. Unfortunately, chemotherapy has a limited effect, with patients responding to treatment for just a matter of months. There is an urgent need for new approaches.
Clarifying a Rare Variant
The members of MSK’s Sarcoma Disease Management Team and the laboratory of world-renowned pathologist and angiosarcoma expert Cristina Antonescu, MD, Director of Bone and Soft Tissue Pathology, have collaborated extensively to create an angiosarcoma research and treatment program that is unparalleled. Kaly’s tumor was an even rarer type of angiosarcoma: It had a mutation in a gene called CIC. Previously, scientists knew little about this mutation. By studying Kaly’s tumor as well as those in our institutional database, we have identified 10 angiosarcomas with a CIC gene rearrangement or mutation. We correlated data from genomic analyses of the tumors with patients’ outcomes and reported our findings in the American Journal of Surgical Pathology in 2016 — one of the first descriptions of this rare and now well-recognized variant of angiosarcoma.
We recently had a paper accepted by Nature Communications describing in detail over 2,500 sarcomas, including more than 100 angiosarcomas, that were genetically profiled through MSK-IMPACT®, a targeted tumor-sequencing test developed at MSK that can detect mutations and other critical changes in 505 genes known to play a critical role in the development and behavior of cancer. This work offers one of the largest angiosarcoma analyses in the world and has provided tremendous insights into this complex disease. The data from the analysis is freely accessible to investigators worldwide who have an interest in angiosarcoma.
Evaluating Immunotherapy for Angiosarcoma
Immunotherapy has become a major pillar of cancer treatment. Kaly received it through a clinical trial, and while it was not effective for her, we observed some dramatic responses in other patients. Based on this encouraging data and your funding, we were able to include patients with angiosarcoma in many of our novel clinical trials assessing immunotherapy drugs in various combinations.
Thanks in part to medical oncologist Sandra D’Angelo, MSK now has one of the largest sarcoma immunotherapy programs in the world. Our patients have access to many new treatment options, including immunotherapy with an injectable modified herpes virus that can multiply in and kill cancer cells, novel immune proteins that help immune cells recognize and travel into tumors, drugs that block the blood vessels that tumors need to grow and spread, and chemotherapies. Through these investigations, we are witnessing different patterns of response among our patients and learning why some angiosarcomas are very sensitive to treatment while others remain resistant.
Through this game-changing work, we have described a subtype of angiosarcoma that develops in the head and neck region due to extensive sun exposure and has a UV genetic signature that makes it especially sensitive to immunotherapy. We are also trying to identify which organ-based angiosarcomas respond to immunotherapy. In one of our efforts, medical oncologist Ciara Kelly showed that the immune system wants to recognize certain angiosarcomas but that immune cells cannot enter the tumor. Rather, they are stuck at the tumor’s edge. However, with the right therapy, we can covert an angiosarcoma that’s resistant to immunotherapy into one filled with cancer-fighting immune cells, and this infiltration results in significant and long-term responses to therapy.
More recently, medical oncologist Evan Rosenbaum evaluated more than 35 people with angiosarcoma who were treated with various immunotherapies at MSK. He performed extensive genomic and pathologic analyses, and correlated his findings with treatment effectiveness, observing that patients with increased signaling in protein pathways called TGF-beta and WNT were more likely to develop treatment resistance. We are using his findings to determine which patients with angiosarcoma are most suitable for immunotherapy and which are not, allowing us to individualize treatment.
Supporting the Future of Angiosarcoma Care
Few places in the world could have performed such comprehensive research on a rare disease like angiosarcoma. This research is expensive and labor-intensive: Expenses for just 10 patients on a single clinical trial can cost hundreds of thousands of dollars, as can all of the correlative genetic and immunological analyses. It also requires the generation of a large clinical database and tissue bank to ensure that we understand and describe the diversity and natural history of this disease, especially for very rare variants like CIC-mutated angiosarcomas.
Your support has been critical and has made much of our efforts possible. This work, along with our international collaborators, has significantly influenced the care we can provide to people with angiosarcoma. At MSK, it has allowed us to build one of the largest angiosarcoma programs in the world, with extensive clinical, research, and scientific expertise focused on eradicating this disease, and it has helped us establish amazing and productive collaborations. We cannot thank you enough for all of your help.
June, 2021
Dear Friends and Family,
Because of all of you, your generosity and continued support, the total money raised for the Kaly Stevens Kris Sarcoma Research Fund ((http://mskcc.convio.net/goto/KalyStevensKris) has exceeded $200,000!
Together, we are helping support the important research at MSKCC to give hope to those diagnosed with sarcoma throughout the world, and supporting the new Adolescent and Young Adult Program recently implemented by Dr.Tap and his team. This program gives much needed social and psychological support to this special group of patients at a time when a diagnosis of cancer interrupts what should be an exciting step towards independence, the start of careers and family beginnings. An update from Dr.Tap’s office outlining some of these new programs is now available through the following link: https://www.mskcc.org/msk-news/fall-2020/bridging-gap-recognizing-unique-needs-adolescents-and-young-adults-treated-msk.
Kaly’s Crew Sedona 2022 Update- Save the Date: Saturday, February 5, 2022
We recently got the optimistic news from RunSedona that the Sedona Half Marathon/10K/5K has been tentatively scheduled. This is an adults and kids friendly event, so, with a bit of planning, we hope more will be able to join us. Become a Kaly’s Crew Team Member and help us fundraise. Last event in 2020 raised $21,980!
Details will be sent closer to the event.
You are all so very important to us for your continued support of Kaly’s memory and to those you help through your donations.
We sincerely thank you,
David. Marian and Rob
PS. For those who prefer to make future donations by check, rather than through the website, please use the Major Gifts office’s new address, indicating that the donation is designated for the Kaly Stevens Kris Sarcoma Research Fund:
Memorial Sloan Kettering Cancer Center, Office of Development
Attention: Emily Carter
PO Box 27106
New York, NY 10087
UPDATE TO ANNUAL UPDATE!
November, 2020
Dear Friends,
Please note: The Kaly’s Crew Sedona 2021 event, originally scheduled for February 2021, has been postponed due to Covid19 restrictions. When a new date is announced the information will be forwarded.
Since we were unable to provide a research update in the June 2020 Update letter, we are pleased to send an update to this past year’s annual letter to announce a new initiative created by Dr. Tap and his sarcoma group, “The Adolescent and Young Adult Program” for sarcoma patients. Your donor dollars to the Kaly Stevens Kris Sarcoma Research Fund (http://mskcc.convio.net/goto/KalyStevensKris) will be invaluable in helping further this mission to address the unique research needs, treatment approaches and social/ psychological needs of this very special group of patients aged 15 to 40.
Below is an outline of the newly created program at Memorial Sloan Kettering Cancer Center
Please consider including the Kaly Stevens Kris Sarcoma Research Fund in your year end giving, perhaps during the annual event, “Giving Tuesday”, this year on Tuesday December 1. An anonymous donor has pledged to make a $10,000 match if a total of $10,000 in donations is made to the Fund from now until December 31. This very generous addition to the Fund would be incredible!
We wish you all a very peaceful, healthy and happy end of 2020 and a Happy New Year!
With our sincerest thanks,
David, Marian and Rob
AYA@MSK: Transforming Cancer Care for Adolescents and Young Adults at MSK and Worldwide November 2020
Prepared for: Kaly Stevens Kris Fund
Adolescence and young adulthood are times of rapid change, growth, and discovery: education is completed, careers are launched, and relationships, including marriage and parenthood, are pursued. When someone between the ages of 15 and 40 is diagnosed with cancer, this momentum is suddenly interrupted, which can cause unique emotional and psychosocial challenges. While cancer is relatively rare for adolescents and young adults (AYAs), it remains the age group’s leading cause of disease-related death. The most common AYA malignancies are sarcoma, leukemia, lymphoma, thyroid and colon cancers, and germ cell, brain, and spinal tumors. In the US, approximately 70,000 AYAs are diagnosed with cancer each year, and Memorial Sloan Kettering Cancer Center (MSK) treated almost 15,000 in 2019. These patients are traditionally underrepresented in research and as a result have seen fewer benefits from recent advances in cancer care than children or older adults.
In both pediatrics and older adult medicine, there is a focus on creating evidence -based care continuums that address patients’ medical and psychosocial needs. This has not been the case for AYA patients. Depending on many arbitrary factors such as diagnosis, referring physician, and the hospital in which they are cared for, they may be treated as kids or older adults, with their distinct needs ignored. Medical providers, too often untrained in the specifics of this age group, may not have the information necessary to refer patients to adequate and appropriate social supports. In addition, very few clinical trials exist to test how this cohort responds to therapies and whether their genetic make-up plays a role in drug response and overall outcome.
To address these gaps and improve the experience, care, and outcomes of AYAs with cancer, William Tap, MD, Chief of the Sarcoma Medical Oncology Service, and Julia Glade Bender, MD, Vice Chair of Clinical Research at MSK Kids, have launched the Adolescent and Young Adult Program at Memorial Sloan Kettering (AYA@MSK). By incorporating the expertise, resources, research, and clinical trial opportunities of pediatric and adult oncology, we are developing an optimized continuum of care to address AYAs’ biopsychosocial needs using an integrated approach that bridges pediatric and medical oncology and supportive services.
As a world-renowned center of excellence for sarcomas, MSK treats a high number of AYAs with these diseases—approximately 2,000 per year. Therefore, we initially launched AYA@MSK with sarcoma patients and will soon expand it to patients with other diagnosis.
June, 2020
Dear Friends and Family,
For the past few months we have all been concentrating on the current health crisis created by Covid19, challenged to do our part to stay healthy and protect those around us. So it is especially important that we reach out to all of you during this most unprecedented time with our thanks for your support this past year, as in other years, for the Kaly Stevens Kris Sarcoma Research Fund (http://mskcc.convio.net/goto/KalyStevensKris) and our hope that you are all healthy and safe.
This year marks the fifth anniversary of continued support and generosity from all of you for Kaly’s Research Fund. In the initial year, we were touched by the outpouring of donations in Kaly’s memory, Now, five years later, the fund has raised more than $191,000 over the years, an incredibly significant amount for a grassroots effort, and one that wouldn’t be possible without your contributions, year after year, to help make a difference, and give hope through the research.
Perhaps the highlight of this year’s effort was the Kaly’s Crew Sedona 2020 event held in February, raising over $21,000. The event itself was an incredible coming together to honor Kaly on a beautiful weekend, in a magnificent location, and with those unable to attend sending well wishes and support from afar. A special thanks to Mark, Peggy and Carol for helping expand the donor reach through their own Fred’s Team Kaly’s Crew Team member pages. Seventeen friends and family were able to join us in Sedona for this event. From that success, we planned to make this an annual event, participating once again in the Sedona Half Marathon/10K/5K as Kaly’s Crew Sedona 2021 on February 6. With the heartfelt wish and optimism that the current health crisis resolves and allows us all to get back to some semblance of “normal”, save the date and join us!
In the past, we have attached a research update from Dr. Tap to give an idea of how your donations have been used over the past year. With the current medical situation so difficult for all New York City health facilities and healthcare workers, especially those at MSKCC dealing with the vulnerable cancer patient population, we are not requesting an update this year so as not to put an extra burden on staff to gather that information.
With our thanks.
David, Marian and Rob
July, 2019
Dear Friends and Family,
Because of your ongoing support of Kaly’s wish to further the research efforts to find better treatments and, ultimately, a cure for sarcoma, the Kaly Stevens Kris Sarcoma Research Fund ( http://mskcc.convio.net/goto/KalyStevensKris) has reached a donation total of over $152,000 since its inception four years ago. This is a wonderful tribute to your love and support of Kaly and for those who will benefit from the research. Attached below is a summary of the past year’s research efforts and achievements of the team who continue to pursue the Fund’s goals with the help of your donations. We are so grateful for your continued support!
Upcoming Kaly’sCrew Event- Sedona Arizona, February 1, 2020
Join us for the first (and, hopefully annual) Kaly’sCrew event at the Sedona Half Marathon/10K/ 5K in beautiful Sedona Arizona on Saturday February 1, 2020.
We are in the preliminary stages of organizing a team of participants, with the help of Fred’s Team at Memorial Sloan Kettering, to create a team website and individual fundraising page for participants to send to their friend’s and family to encourage a wider network of donors. Join the team or support our efforts through a donation on the team’s website. All donations will go directly to the Kaly Stevens Kris Sarcoma Research Fund. There will be no mandatory donation requirements to sign up through the team website, or mandatory fund raising goals as is the case for some of the teams participating in bigger races that Fred’s Team helps organize.
Sedona was Kaly’s favorite hiking spot, renowned for its natural beauty of the red rocks. This will be a very special way to celebrate Kaly and to further her goal to support research. And we’ll have some fun and good exercise! Participants register for either the half marathon, 10K or 5K distance on the registration sight for RunSedona (sedonamarathon.com) and can either run or walk the distance. David and Marian plan to walk the 10K course. The average temperature in Sedona for the race is usually 50 degrees at race start at 8:00 am, with highs in the 60’s, perfect for running or walking.
To join the fundraising team please contact Marian for further information at ksksrfund@gmail.com, or 928-853-1655.
We hope to see many of you in Sedona!
With our sincere thank you for your continued interest ands support for our efforts, David, Marian and Rob
Research Update:
New Combination Therapies
A multi-center pilot study has recently been completed of the checkpoint inhibitor NKTR214 plus nivolumab in patients already treated for sarcoma and/or for whom treatment has stopped working. As presented at the 2019 ASCO meeting, the group found this to be a safe and tolerable combination, with certain forms of sarcoma showing an ongoing response. Patients with the sarcoma subtype known as dedifferentiated liposarcoma experienced the most prolonged disease stability. Enrollment continues with plans to add a group of never-before-treated patients to evaluate efficacy as initial treatment.
...
June, 2018
Dear Friends and Family,
Another year has rolled around, this one marking the third anniversary of Kaly’s passing and the establishment of the Kaly Stevens Kris Sarcoma Research Fund. As of this month, over $138,000 has been raised to support the much needed research to better understand the disease and to find more effective treatments and therapies. This would not be possible without your continued support and understanding of the importance of the work being done. And we are so grateful that you choose to honor Kaly’s memory in such a meaningful way.
Below is an update from Dr. Tap’s research team at Memorial Sloan Kettering Cancer Center on their research efforts. Their findings are continually shared with other Sarcoma specialists throughout the world, increasing the impact of their work and integrating their findings with that reported at other research sites. All the small steps are what lead to a major breakthrough!
A REMINDER:
Should you wish to make a donation to the Fund to honor someone, or a milestone event, or to make a donation in memory, contact Marian (KSKSRfund@gmail.com) and she will arrange for an acknowledgment of your donation be sent directly from the Development Office at Memorial Sloan Kettering to the person honored or family whose loved one was remembered, notifying them of your kind gesture.
And should you wish to organize a Kaly’s Crew fundraising event, let Marian know so she can facilitate assistance from the Development Office.
A Brand New Finding in Cell Biology: Innovative Drug Options for a Difficult-to-Treat Sarcoma
When cancer does not respond to chemotherapy, or becomes resistant to chemotherapy over time, patients need other options. Over the last year, Dr. Tap and his team made an important discovery about cancer cells’ basic biologic process – and a cell state called “therapy induced senescence” that makes cancer more manageable. It has been well established that the gene CDK4 is active in forms of liposarcoma that do not respond to chemotherapy; armed with this new discovery, Dr. Tap is researching drugs that can inhibit the gene, and to understand the molecular underpinnings of patients’ responses to these treatments. The ongoing goal is to identify which patients—with liposarcoma —require new options to fight their cancer.
We thank you for your continued support,
David, Marian and Rob
June 2017 Fund Update
As we mark the second year since the establishment of the Kaly Stevens Kris Sarcoma Research Fund, we want to thank you for the incredible, continued support you have given to the Fund. As we honor Kaly’s memory we have raised over $117,000 to date that will benefit so many through the research that the fund helps support. We share, below, an update on the research that your donations have helped fund, and information about a new fundraising campaign called “Kaly’sCrew” With your help, our grassroots fundraising will continue to further much needed research of these rare types of cancer that are so often underfunded.
Last year’s letter focused on MSK’s efforts around precision, or personalized, medicine. If a patient’s tumor can be deeply analyzed and the genetic underpinnings within the cancer identified, these very specific mutations can be targeted with powerful therapies. The results can be incredible, with fewer side effects. MSK is one of the leading forces behind this concept—certain to transform how cancer is understood and managed.
This year, Dr. Tap and his group have made huge strides in his quest to bring personalized medicine to their patients. They use a technology invented at MSK—called MSK-IMPACT—to characterize, on a genomic level, the tumors of more than 400 sarcoma patients. MSK-IMPACT looks for any of the 468 genetic mutations known to play a role in cancer. If one of these “aberrant” genes is spotted, MSK’s experts can attack it with new drugs—and potentially alter the course of a person’s disease. One of the primary interests of Dr. Tap’s team is using MSK-IMPACT to advance research in angiosarcoma. A member of Kaly’s treatment team, internationally-renowned pathologist Dr. Cristina Antonescu, is researching the molecular mechanisms within these tumors. One of her top goals is to understand how and why drugs stop working and resistance begins. She is working to identify a number of mutations present in angiosarcoma—which can be eventually be targeted with drugs.
In addition to the incredibly generous individual donations from family and friends, a new fundraising arm for the Kaly Stevens Kris Sarcoma Research Fund was started last year. “Kaly’sCrew”, an event team fundraising effort, debuted in September 2015 as a team of runners participating in the 2015 New York City Marathon, raising funds through the team’s website, with all money raised going directly to the Kaly Stevens Kris Sarcoma Research Fund. The momentum was continued with a Kaly’sCrew team running in the 2016 Boston Marathon. This past November, Kaly’sCrew was, once again, represented in the 2016 New York City Marathon. And, also in November, a Kaly’sCrew participated in the 2016 Philadelphia Marathon. Collectively, their fund raising success has been astounding!
If you are a weekend athlete, whether a runner, walker, cyclist or, whatever, join an existing event, or organize one in your community and set up a Kaly’sCrew” team website to help raise money that will go directly to Kaly’s Research Fund. For guidelines and support for your event, get in touch with Marian (KSKSRFund@gmail.com, or 928-853-1655).
We are so very grateful for your continued support,
David, Marian and Rob
June 2016 Fund Update
As the one year anniversary of theestablishment of the Kaly Stevens Kris Sarcoma Research Fund approaches we wanted to thank you again for your very generous support and to give you an overview of how the funds have been used so far. To date, the Fund has received over $85,000 in donations. An update from Kaly’s oncologist, Dr. William Tap, Chief, Sarcoma Medical Oncology Service at Memorial Sloan Kettering, who is overseeing the use of the funds, is below, giving details of his ongoing efforts to search for better treatments and a cure.
So many donated to Kaly’s Research Fund to honor Kaly’s memory and to give hope to others facing a similar diagnosis. We are so grateful for that support.
With our utmost thanks,
David, Marian and Rob
Dr. Tap and his colleagues at Memorial Sloan Kettering Cancer Center have just recently published their findings in the “American Journal of Surgical Pathology” after carefully studying the genetic makeup of angiosarcoma tumors, and, specifically, the genetic complexity and unusual cell type of Kaly’s particular tumor. The findings revealed that, in many cases, pathology alone is not enough to diagnose and predict response to certain types of treatments. Specifically, it was found that in young adults, it was especially important to do a full genetic screening for tumor makeup to truly identify the genetic heterogeneity in each individual diagnosis of angiosarcoma in order to form a treatment plan. Through this research, oncologists worldwide will be able to readily access these findings when presented with a young adult patient diagnosed through pathology with angiosarcoma . It will be recommended that tumor type be screened genetically to help refine therapy options.
The next step is to further study the genetic mutations driving the cancer and discover the point at which the mutation occurs during cell development. Once understood, new therapies may be developed to specifically target these mechanisms and halt tumor growth. The money raised so far will help fund this further research, under the guidance of Pathologist Cristina Antonescu, MD, a leading Sarcoma specialist, who was involved in Kaly's treatment and care, and fund the hiring of a Research Technician to assist her.
$0
Goal
Goal
$281,553
Total Raised
Donors
Regina Loughran & Ed Taylor
Florence Long
Shane Giuliani
Brittany Sonnichsen & Hooman Adamous
Dottie & Jerry McCann
The Kris-Smith Family
Opower
Jim and Barb Bilhorn
Hayes Elmore
Tom & Elizabeth Harp
Anonymous
Lee Krug
Hailey and Nate Levinson
Linda L. Lum
Carmen Luna
Emmie Majka
Michael and Ellen Martin
anne mc sweeney
Inpatient TOS NP's
Margot Murphy
Denise O'Rourke
Vivian Phillipaitis
Margaret Lippitt Prust
Jack & Joal Russell
Friends in L/HRR
Anonymous
Shereen Taylor-Berger and Steve Berger
Cassandra Virgin
Frishta Yazdani
Robert Kris
Lauryn & Ryan Nelson
Sean & Melissa Hutchinson
Eleanor Bilhorn & Max Levin
Ange
RICHA BHALA & GUSTAVO ARDILA
Elizabeth Campbell
Barry Skidmore and Kathleen Flahive
Dr. Sari Hornstein
Melissa Johnson
Katie Kaplun
Rick and Barb Magnan
Renée Monrose
Shirah Neiman
Jana Ramsey
Kari and Greg Riely
Matt Sargenti
Anonymous
Bob and May Summers
Reem Sweiss
Morgan Taylor
Kaly's Crew Sedona 2023
Florence Long
Scott & Crystal Bilhorn
Jess and Patrick
A.J. Brown and David Young
Jim and Mary Griffith
The Applen Family
Jeffrey Bailin
Anna Baldasty
Alan Berlow and Susan Blaustein
Anonymous
Beth A. Goldstein
Clare Malone
JD Marlow & Amanda Bergeron
Cori Martin
The O'Mahoney-Schwartz Family
Laura, Ossama and Noah
Amanda Porter
Alex Ramirez
Daniel Robles
Sarcoma Sucks
Elaine and Dennis Silashki
Robin solod
Cailin Sousa
Erin Sousa
Nancy and Alan Stein- In Memory of Mary Stevens
Friedell Family
Elyssa & James Wenzel
Friends from IO/HRH (Mary Gardner, Liz, Ethan, Wes, Phil, April, Elizabeth)
Kaly's Crew Boston Marathon 2016
Kaly's Crew NYC Marathon 2015
A.J. and David's Wedding
Alan Berlow and Susan Blaustein - The Melrose Fund
With love, D & M, 4/23/24
Always in my heart. With love and hope, AP.
Mark and Mary Ellen Kris
Christopher Katsaros
Elizabeth Lord
Roger & Nancy Applen
Patricia Albanese
Anonymous
Anonymous
David and Mary Best
Colorado Nurses Association
Anonymous
John and Conchita Foster
Kenneth Gillette
Dave Hrabe and Sandy Somers
K Karpen
Carol Krakowski
Bob & Mary Loughran
Jack Martin and Laurie Bilhorn Martin
THOM & LAURA O'HARA
Nancy Powers
Erin Rahman
Ryan and Alexandra Sturgill
Robin Rector
Eric Reese
Eric Richardson
Anonymous
Paula Schriefer
Ted Scofield Family
Brandon and Vanessa Seher
Josh and Zaree Singer
Leesa and Robert Sonnichsen
Anonymous
Stacy Weiss Wilmouth
Jim and Barb Bilhorn July 2023
Frank and Sue Parks
Kaly's Crew Sedona 2020
Happy Heavenly Birthday Kaly! Love and miss you so much! Aunt Nan
Daniela, Tommy & Arianna Rizzo
Cynthia & Stephen Clancey
Stephanie Bean
Elissa Calloway
Suzanne Evans and Melonie Orr
Nancy and Herb Fall
Amy & Mark Gerner
Anonymous
Rob Hodin
Mary Kennedy
Sarah Lundquist Nuutinen
Dr. Anne McNamara
Emily Muller
Eliot C Nelson
Colleen O'Brien
Anonymous
Antrice Scott
Solmaz Sharifi
Erin and Dave Shevlin
Anonymous
Anonymous
Tushman, M.D.
Blair Udwin
Alejandra Villarreal and Jimmy Weiss
Jerry and Karen Jacquet
Edward Taylor
D & M, Christmas 2023
Amanda Evans & Adam Reis
Carol Stevens
Shelly, Matt & Annie Clancey
Christopher Applen and Family
Matthew Appenfeller
Natalie Baer
Dennis, Kathy and Ryan Black
Kelly Clarke
Ray and Elizabeth Clifford
Anonymous
The Ehrenberg/Paul Family
Juliana Eng
Helen Finnigan
Kirk Francis
Jerry & Beryl Halladay
Clay Holk
Sean and Melissa Hutchinson
Bill and Mary Claire Knapp
Sara & Chris Lamar-Sterling
Sarah Lewin
Andres Martinez
Alexandra O'Brien
Jessica Reis
Nathalie Rennell
Mark Rodgers
Bill & Judy Shillady
In Memory of Mary Stevens, The Soppa's
Jenna Winokur and Bryan Alban
Dan Yates
Anonymous
Marjorie Zauderer & David Griffel
Kaly's Crew 2016 NYC Marathon
Kaly's Crew Philadelphia Marathon 2016
In Memory of Jim Woods - The James Woods Foundation
In loving memory of Kaly, Nancy Applen
Mary Enright
Mary Kiernan Kris
Evan Smith
Pam Brighton and Mirko Cavar
Jim and Barb Bilhorn
Adah Berkovich
Shirin Baskey
Melissa & Eric Sobel
Anonymous
Anonymous
Keith & Dalya Danish
Anonymous
Joe & Lilah Loughran
Matt & Gretchen Markiewicz
Emma Marwood
Marlene Nadel & Robert Stolz
Clare Orvis
Cathy Pietanza
Michelle Pilloff and Mike Lewis
Jerome Sherman
Peter Sorrentino
Nathaniel Tavel
Jane Wakeman, Deaconess
Anne & Jim White
Aimee Zimmermann
Bill & Elizabeth Rahr
David and Marian Stevens, In loving memory of Kaly
Peter& Marilyn Grylls
Michael O'Neill & Ana Maria Thomas
Bill and Elizabeth Rahr
With love and hope AMLA, AP
Scott & Kathy Deasy
Remembering my beautiful niece on her birthday, Aunt Carol
Meghan Apfelbaum
Gaby Baca
Berin Bezmen
Kathleen and Charlie
Aryeh Caroline
Ben Cavar
Katharine Davis
Amanda Amato Estrada
Joe & Marie Flahive
Anonymous
SIA Colleagues
Matthew Hellmann
Pam (Hickey) Hawkins from Gore
Vanessa and Brian Kehoe
Mariclaire Petty
Kelly and Michael Piatek
Meg Pickering
Alison Rapoport
Bob Reger
Gordon, Joanne, Bethany, Jill
In Memory of Mary Stevens, Dave Hrabe and Sandy Somers
For the family, Love D&M
Jeremy & Emily Thomas
Jennifer Walter
Pastor Jeff Wells
In memory of Mary Stevens -Linda & Pete Werner
Danny White
Mark E.and Terry Bilhorn Widmer
Anonymous
Jamie Zigerelli
In memory of Kaly's wonderful uncle Roger, Peggy
This web page and e-mail are provided as a courtesy to participants to help them manage fundraising efforts for this event. Memorial Sloan Kettering Cancer Center or any of its affiliated organizations, or their officers, directors, agents, or employees do not control, nor are they responsible for, the contents of this Web page. Any views or information provided on this Web page are the sole responsibility of the participant. The participant's Web page may provide links to other Web sites and does not imply an endorsement by MSKCC, its affiliated organizations, their officers, directors, agents, and employees of the materials contained at those Web sites. |
If you think this page contains objectionable content, please
inform the system administrator.